Sonde Health

Sonde Health

Sonde Health was founded to commercialize voice biomarker technology originally developed at MIT's Lincoln Laboratory. The company uses machine learning to analyze subtle vocal features—such as pitch, jitter, and breathiness—that correlate with health conditions. Its platform processes audio clips of just a few seconds to deliver real-time health assessments. The firm's strategy centers on licensing its software development kit to healthcare providers, insurers, and telehealth platforms rather than building consumer-facing applications directly. Sonde Health has validated its technology across multiple clinical studies, including partnerships with institutions like Boston Children's Hospital and the University of Massachusetts. The platform covers conditions such as chronic obstructive pulmonary disease, asthma, stress, and depression. Sonde Health operates primarily in North America but has explored deployments in Asia. Sonde Health has not disclosed its AUM, team size, or funding history. The company is privately held and has not publicly revealed investor names or revenue figures. Its team likely includes engineers, data scientists, and clinical researchers based in Boston. The firm received early support from the MIT Sandbox Innovation Fund. No philanthropic foundation or adjacent investment vehicles have been disclosed. Sonde Health's structural differentiation lies in its proprietary voice biomarker database, which contains millions of labeled voice samples collected across diverse populations and languages. That dataset provides a competitive moat against other audio-based health startups. The firm's business model—licensing its SDK rather than marketing a direct-to-consumer app—positions it as an infrastructure provider in digital health, not a brand competing for patient engagement.